Age-Dependent Decrease in Hepatic Geranylgeranoic Acid Content in C3H/HeN Mice and Its Oral Supplementation Prevents...

Area of Science:

• Biochemistry
• Oncology
• Gerontology

Background:

• Geranylgeranoic acid (GGA) shows promise in preventing secondary liver cancer (hepatoma).
• Previous research indicates GGA induces hepatoma cell death via TLR4-mediated pyroptosis.
• Endogenous GGA is biosynthesized from mevalonic acid and found in various organs.

Purpose of the Study:

• To investigate age-related changes in hepatic GGA levels in mice.
• To evaluate the potential of GGA supplementation in suppressing spontaneous hepatocarcinogenesis.
• To explore the link between GGA biosynthesis and age-related liver cancer development.

Main Methods:

• Measurement of endogenous GGA and monoamine oxidase B (MAOB) mRNA in the livers of male C3H/HeN mice across a range of ages (6-93 weeks).
• Administration of GGA to assess its effect on spontaneous hepatocarcinogenesis.
• Dose-dependent analysis of GGA and geranylgeraniol supplementation on hepatic GGA content.

Main Results:

• Hepatic GGA content and MAOB mRNA expression decreased with age in male C3H/HeN mice.
• A single oral GGA administration at 11 months significantly reduced hepatoma incidence and size at 24 months.
• Oral GGA and geranylgeraniol supplementation dose-dependently increased hepatic GGA; zaragozic acid A (ZAA) markedly upregulated it.

Conclusions:

• Hepatic GGA levels decline with age in male C3H/HeN mice.
• Early-life GGA administration is an effective strategy for preventing spontaneous hepatoma.
• Maintaining adequate GGA levels may be crucial for mitigating age-related liver cancer risk.